RET and medullary thyroid gland carcinoma: Among the multi-tyrosine kinase inhibitors (MKI) (Figure 4), vandetanib and cabozantinib were approved in 2011 and 2012, respectively, as first line therapies for advanced MTC, regardless of RET mutational status.